

## Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture

Hui-Hsuan Kuo,<sup>1,2</sup> Xiaozhi Gao,<sup>1,2</sup> Jean-Marc DeKeyser,<sup>1,2</sup> K. Ashley Fetterman,<sup>1,2</sup>  
Emily A. Pinheiro,<sup>1,2</sup> Carly J. Weddle,<sup>1,2</sup> Michael V. Orman,<sup>1,2</sup> Marisol Romero-Tejeda,<sup>1,2</sup>  
Mariam Jouni,<sup>1,2</sup> Malorie Blancard,<sup>1,2</sup> Tarek Magdy,<sup>1,2</sup> Conrad Epting,<sup>3</sup>  
Alfred L. George, Jr.,<sup>1,2</sup> Paul W. Burridge<sup>1,2,\*</sup>

<sup>1</sup>Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

<sup>2</sup>Center for Pharmacogenomics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

<sup>3</sup>Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

\*Correspondence: [paul.burridge@northwestern.edu](mailto:paul.burridge@northwestern.edu)

**Keywords:** human induced pluripotent stem cell; pluripotent state; culture media; weekend-free; differentiation

## Summary

Human induced pluripotent stem cell (hiPSC) culture has become routine, yet pluripotent cell media costs, frequent media changes, and reproducibility of differentiation have remained restrictive, limiting the potential for large-scale projects. Here, we describe the formulation of a novel hiPSC culture medium (B8) as a result of the exhaustive optimization of medium constituents and concentrations, establishing the necessity and relative contributions of each component to the pluripotent state and cell proliferation. B8 eliminates 97% of the costs of commercial media, made possible primarily by the in-lab generation of three *E. coli*-expressed, codon-optimized recombinant proteins: an engineered form of fibroblast growth factor 2 (FGF2) with improved thermostability (FGF2-G3); transforming growth factor  $\beta$ 3 (TGF $\beta$ 3) - a more potent TGF $\beta$  able to be expressed in *E. coli*; and a derivative of neuregulin 1 (NRG1) containing the EGF-like domain. The B8 formula is specifically optimized for fast growth and robustness at low seeding densities. We demonstrated the derivation of 29 hiPSC lines in B8 as well as maintenance of pluripotency long-term, while conserving karyotype stability. This formula also allows a weekend-free feeding schedule without sacrificing growth rate or capacity for differentiation. Thus, this simple, cost-effective, and open source B8 media, will enable large hiPSC disease modeling projects such as those being performed in pharmacogenomics and large-scale cell production required for regenerative medicine.

## Introduction

Human induced pluripotent stem cells (hiPSCs) are functionally immortal and can proliferate without limit while maintaining the potential to differentiate to, hypothetically, all ~220 cell lineages within the human body. hiPSC generation has become routine due to the simplicity of amplification of CD71<sup>+</sup> blood proerythroblasts (Chou et al., 2015; Chou et al., 2011; Tan et al., 2014) or myeloid cells (Eminli et al., 2009; Staerk et al., 2010) and commercial Sendai virus-based reprogramming factor expression (Fujie et al., 2014; Fusaki et al., 2009). This simplicity has resulted in increased enthusiasm for the potential applications of hiPSC-derived cells across many fields, including regenerative medicine, disease modeling, drug discovery, and pharmacogenomics.

However, these applications require the culture of either large quantities of hiPSCs or hiPSC lines derived from large numbers of patients, and three major restrictions have become evident: 1, the cost of large-scale pluripotent cell culture, which is prohibitive for high patient-number projects; 2, the time-consuming requirement for daily media changes, which is particularly problematic for laboratories in industry; 3, inter-line variability in differentiation efficacy, which is highly dependent on pluripotent culture consistency and methodology. Our understanding of the media conditions required to culture human pluripotent stem cells has progressed steadily over the last 15 years, with significant breakthroughs coming from the discovery of the necessity for high concentrations of FGF2 (Xu et al., 2005), the use of TGF $\beta$ 1 (Amit et al., 2004), and the elimination of knockout serum replacement (KSR) with the TeSR formula which contains 19 components (Ludwig and Thomson, 2007; Ludwig et al., 2006a; Ludwig et al., 2006b), followed by the first robust chemically defined formula, E8 (Beers et al., 2012; Chen et al., 2011) which consists of just 8 major components. A number of alternative non-chemically defined pluripotent formulations have been described including: CDM-BSA (Hannan et al., 2013; Vallier et al., 2005; Vallier et al.,

2009), DC-HAIF (Singh et al., 2012; Wang et al., 2007), hESF9T (Furue et al., 2008; Yamasaki et al., 2014), FTDA (Breckwoldt et al., 2017; Frank et al., 2012; Piccini et al., 2015), and iDEAL (Marinho et al., 2015) (**Figure S1A**).

Each of the available formulations consist of a core of three major signaling components: 1, insulin or IGF1 which bind INSR and IGF1R to signal the PI3K/AKT pathway promoting survival and growth; 2, FGF2 and/or NRG1 which bind FGFR1/FGFR4 or ERBB3/ERBB4 respectively, activating the PI3K/AKT/mTOR and MAPK/ERK pathways; and 3, TGF $\beta$ 1, NODAL, or activin A which bind TGFBR1/2 and/or ACVR2A/2B/1B/1C to activate the TGF $\beta$  signaling pathway. NODAL is used less commonly in pluripotent media formulations due to the expression of NODAL antagonists LEFTY1/2 in human pluripotent stem cells (hPSC) (Besser, 2004; Sato et al., 2003) resulting in a requirement for high concentrations *in vitro* (Chen et al., 2011). In addition, numerous growth factor-free formulae utilizing small molecules to replace some or all growth factors in hPSC culture have been described (Burton et al., 2010; Desbordes et al., 2008; Kumagai et al., 2013; Tsutsui et al., 2011), however, these have not successfully translated to common usage. Recently, a growth factor-free formula AKIT was demonstrated (Yasuda et al., 2018), combining inhibitors of GSK3B (1-azakenpaulone), DYRK1 (ID-8), and calcineurin/NFAT (tacrolimus/FK506), albeit with much reduced proliferation and colony growth, as well as increased interline variability in growth. Finally, more than 15 commercial pluripotent media are also available in which the formulae are proprietary and not disclosed to researchers. These media represent the major cost for most hiPSC labs and considerably restrict research efforts. Some of these media formulae are suggested to support hiPSC growth without daily media changes or ‘weekend-free’, likely by using heparin sulfate to stabilize FGF2 that otherwise degrades quickly at 37 °C (Chen et al., 2012; Furue et al., 2008) and including bovine serum albumin (BSA) which acts as a multifaceted antioxidant.

Here, we demonstrate a novel media formula (B8), thoroughly optimized to support high growth rate under low seeding density conditions, require minimal media exchanges, and at low cost, while maintaining differentiation reproducibility. This formula is capable of supporting both hiPSC generation and culture for >100 passages. Generation of B8 supplement aliquots suitable for making 100 liters of media is simple for any research lab with basic equipment, with complete bottles of media costing ~\$12 USD per liter. A full protocol is provided, including detailed instructions for recombinant protein production in three simple steps. All plasmids for protein production are available through Addgene. With the commoditization of these protocols, we believe it is possible to substantially increase what is achievable with hiPSCs due to the near elimination of pluripotent cell culture costs and minimization of labor associated with cell culture.

## Results

### Optimization of Media Constituents with a Short-Term Assay

We began with simple cost-reductions to our existing hiPSC culture medium formula based on E8 that we have used extensively (**Figure 1A**). First, we optimized suitable concentrations of matrices on which the hiPSCs are grown. Although laminin-511 (Rodin et al., 2010), laminin-521 (Rodin et al., 2014), vitronectin (Braam et al., 2008), and Synthemax-II (Melkounian et al., 2010) are suitable for hiPSC culture (Burrige et al., 2014), none are appropriately cost-effective, and in the case of vitronectin or Synthemax-II, also not suitable for subsequent differentiation (Burrige et al., 2014). Matrigel, although an undefined product (Hughes et al., 2010), is a cost-effective and commonly used matrix with substantial data using it at 50  $\mu\text{g cm}^{-2}$  (Ludwig et al., 2006a). Comparing two similar commercial products, Matrigel (Corning) and Cultrex/Geltrex (Trevigen/Gibco), we found that both be used at concentrations as low as 10  $\mu\text{g cm}^{-2}$  (a 1:1000

dilution) (**Figure S1A**) and were subsequently used at a conservative 1:800 dilution for all future experiments.

We next established a suitable pluripotent growth assay modeled on that used by Ludwig *et al.* and Chen *et al.* after establishing that neither automated cell counting of dissociated cells (6-well) or small format survival assays (i.e. 96-well) were suitably robust (**Figure 1B**). We utilized this 6-day protocol rather than our typical 4-day protocol to enhance the detection of variance between formulae during sub-optimal low-density culture. All initial experiments were performed using a version of FGF2 we generated in-house with a mutation (K128N) previously demonstrated to enhance thermostability (Chen *et al.*, 2012). In a first round of optimizations we assessed a range of concentrations for each of the six major hiPSC medium components (**Figures 1C-H**). During this stage we established that insulin was essential and could only be replaced by very high levels of IGF1 LR3 ( $\geq 1 \mu\text{g ml}^{-1}$ ), although this was not cost-effective (**Figure 1C**). The effect of insulin was dose-dependent up to  $20 \mu\text{g ml}^{-1}$ . Ascorbic acid 2-phosphate was not essential, as previously demonstrated (Prowse *et al.*, 2010), but higher levels ( $\geq 200 \mu\text{g ml}^{-1}$ ) enhanced growth (**Figure 1D**). Of note, this level of ascorbic acid 2-phosphate is similar to the level optimized in the cardiac differentiation media CDM3 (Burridge *et al.*, 2014). Transferrin was also not essential to the media formula, but improved growth in a dose-dependent manner with  $20 \mu\text{g ml}^{-1}$  exhibiting optimal growth while maintaining cost-efficiency (**Figure 1E**). A source of selenium was shown to be essential, although concentrations of sodium selenite between 2-200  $\text{ng ml}^{-1}$  did not significantly affect growth, and sodium selenite became toxic at  $\geq 200 \text{ng ml}^{-1}$  (**Figure 1F**). FGF2-K128N was optimal at  $\geq 40 \text{ng ml}^{-1}$  (**Figure 1G**), and TGF $\beta$ 1 was sufficient at  $\geq 0.5 \text{ng ml}^{-1}$  in this simple one passage growth assay (**Figure 1H**).

## Optimization of Additional Media Components

In previous work, Chen *et al.* show that transferrin improves single cell clonality in the absence of the Rho-associated kinase (ROCK1/2) inhibitor Y27632. We could not replicate this observation in our assay (**Figure 2A**) suggesting that the inclusion of a ROCK1/2 inhibitor for at least the first 24 h after passage is optimal. We also confirmed that the addition of 2  $\mu\text{M}$  thiazovivin for the first 24 h marginally, though not significantly, improved growth over 10  $\mu\text{M}$  Y27632 and was  $\sim 5 \times$  more cost-effective choice (**Figure 2B**). Some recent hiPSC growth formulae have suggested that the addition of high levels ( $2 \times$ ) of non-essential amino acids (NEAA) and/or low levels ( $0.1 \times$ ) of chemically defined lipids enhance growth (**Figure S1B**). In our assay NEAA did not augment growth and the addition of lipids was inhibitory at all but the lowest levels (**Figure 2C**). Supplementation with bovine serum albumin (BSA), a common hPSC media component, did not have positive or negative effects on growth and was excluded to maintain a chemically defined formula (**Figure 2D**). The DMEM/F12 basal media we use from Corning contains higher levels of sodium bicarbonate ( $\sim 29 \text{ mM}$  or  $2438 \text{ mg l}^{-1}$ ) compared to DMEM/F12 from other manufacturers (**Figure S1C**). Supplementation of Gibco DMEM/F12, which contains 14 mM of sodium bicarbonate, with 20 mM of additional sodium bicarbonate has recently been demonstrated to be advantageous to hiPSC growth rate by suppressing acidosis of the medium (Liu *et al.*, 2018). In our hands, the standard 29 mM of sodium bicarbonate was optimal (**Figure 2E**). We also assayed the effect of pH and osmolarity on growth and found that pH 7.1 (**Figure 2F**) and an osmolarity of  $310 \text{ mOsm l}^{-1}$  (**Figure 2G**) to promoted the highest growth rate in contrast to pH 7.2 and  $350 \text{ mOsm l}^{-1}$  demonstrated by Ludwig *et al.* (Ludwig *et al.*, 2006b) or pH 7.4 and  $340 \text{ mOsm l}^{-1}$  used by Chen *et al.* (Chen *et al.*, 2011). Of interest here, low osmolarity KnockOut DMEM ( $270 \text{ mOsm l}^{-1}$ ) has historically been used for mESC culture based on the approximation of mouse embryonic tissue (Lawitts and Biggers, 1992). All of our experiments were optimized for 5%  $\text{O}_2$

and 5% CO<sub>2</sub>, a common compromise for optimal hypoxia which enhances reprogramming efficiency (Chen et al., 2011), pluripotency (Forristal et al., 2010), and genome stability (Narva et al., 2013) without the significant cost increase from high N<sub>2</sub> usage or from 10% CO<sub>2</sub> suggested by some (Ludwig et al., 2006b), that necessitates higher levels of sodium bicarbonate.

In our original hiPSC culture medium formula, we used commercial recombinant human FGF2, and this accounted for >60% of the media cost. This led us to investigate the production of FGF2 in-house, for which we generated a FGF2 sequence with *E. coli*-optimized codon usage to enhance yield and a K128N point mutation to improve thermostability (Chen et al., 2012). This sequence was inserted into a recombinant protein production plasmid (pET-28a) utilizing dual 6×His tags that were not cleaved during purification (**Figure S2**). We subsequently generated two additional thermostable FGF2 variants: FGF1-4X (Chen et al., 2012), and FGF2-G3 (Dvorak et al., 2018). We found FGF2-G3, with nine point-mutations was more potent than FGF2-K128N, showing a similar effect on growth rate at 5 ng ml<sup>-1</sup> to FGF2-K128N at 100 ng ml<sup>-1</sup> (**Figure 2H**).

### **Optimization of Media Components using a Long-Term Assay**

Our initial short-term experiments were useful for preliminary optimizations, yet we were aware from previous experiments that some variables, such as the elimination of TGFβ1, had minimal effects short-term and would only have detectable negative effects in long-term experiments. We began a second round of optimizations using a long-term version of our growth assay covering 5 passages (**Figure 3A**). Each experiment was independently repeated at least 5 times. These experiments again confirmed optimal concentrations of insulin (20 μg ml<sup>-1</sup>; **Figure 3B**), ascorbic acid 2-phosphate (200 μg ml<sup>-1</sup>; **Figure 3C**), transferrin (20 μg ml<sup>-1</sup>; **Figure 3D**), sodium selenite (20 ng ml<sup>-1</sup>; **Figure 3E**), and FGF2-G3 (40 ng ml<sup>-1</sup>; **Figure 3F**).



We next looked for alternatives to TGF $\beta$ 1 as this was now the costliest component (~20% of total cost) and found that this could be used at lower concentrations than previously suggested (0.1 ng ml<sup>-1</sup>) even in a long-term assay (**Figure S3A**). We found that other Activin/NODAL/TGF $\beta$ 1 signaling sources such as NODAL were required at cost-prohibitively high levels (100 ng ml<sup>-1</sup>) (**Figure 3G**), and Activin A was not suitable to maintain growth to the same level as TGF $\beta$ 1 (**Figure 3H**). Activin A in combination with TGF $\beta$ 1 also has had a negative effect on growth (**Figure S3B**). TGF $\beta$ 1 is a homodimer of two *TGFB1* gene products and therefore the recombinant protein is commonly produced in mammalian cells making it complex to produce for basic research labs. These mammalian cells provide post-translational modifications crucial for biological activity such as glycosylation, phosphorylation, proteolytic processing, and formation of disulfide bonds which are not present in *E. coli*. To overcome this issue, we generated a version of TGF $\beta$ 1 (TGF $\beta$ 1m) that is unable to form dimers due to a point mutation. This monomeric protein is predicted to be ~20-fold less potent than TGF $\beta$ 1 but can be easily produced in large quantities in *E. coli* (Kim et al., 2015). Our initial experiments demonstrated the *TGFB1* sequence with *E. coli*-optimized codon usage was expressed in inclusion bodies. To overcome this, we inserted the sequence into a protein production plasmid (pET-32a) designed to produce a thioredoxin fusion protein allowing expression in the cytoplasm. It has been also demonstrated that TGF $\beta$ 3 is more potent than TGF $\beta$ 1 (Huang et al., 2014). Comparing TGF $\beta$ 1, TGF $\beta$ 1m, TGF $\beta$ 3, and TGF $\beta$ 3m, we found that TGF $\beta$ 3 offered the best combination of being able to be produced in *E. coli* and suitable for use at 0.1 ng ml<sup>-1</sup> (**Figures 3I, S3C, and S3D**) and was therefore selected for the final formula.

Finally, two hESC media formulations that we studied, DC-HAIF and iDEAL, contain both FGF2 and neuregulin 1 (NRG1) (**Figure S1B**). We found that supplementation with all tested levels of NRG1 enhanced growth by >15% over FGF2-G3 alone (**Figures 3J and S3E**), although

NRG1 is not able to support growth in the absence of FGF2 (**Figure S3F**). We similarly generated recombinant NRG1 protein using pET-32a, which prevented production as inclusion bodies, with subsequent cleavage using thrombin to form an active protein (**Figures S3G and S4**). Our final B8 media formulation was derived from these long-term assay optimizations and is shown in **Figure 3K**.

### **Demonstration of the Suitability of B8 for hiPSC Generation and Weekend-Free Culture**

The gold-standard demonstration of the suitability of a hiPSC media is the capacity to generate hiPSC lines. We generated hiPSC lines from 26 patients using established protocols but using B8. Lines were successfully generated from all donors and passed standard assays for pluripotency including flow cytometry for SSEA4 and TRA-1-60 (**Figure 4A**), immunofluorescent staining for SSEA4, POU5F1, SOX2, and TRA-1-60 (**Figure 4B**), and karyotype stability (**Figure 4C**). We then compared this B8 formula (**Figure 3K**) with our traditional E8 formula and found that growth similar to B8 across commonly used split ratios (**Figure 4D**). It has been demonstrated that unlike commercial FGF2, thermostable variants of FGF2 such as FGF2-G3 are capable of inducing pERK in FGF-starved cells, even after media had previously been stored for extended periods at 37 °C (Chen et al., 2012; Dvorak et al., 2018). To confirm that our FGF2-G3 performed similarly we performed a comparable assay and corroborated that FGF2-G3 was stable after 7 days at 37 °C, whereas commercial FGF2 was not capable of stimulating pERK after 2 days at 37 °C. As common ‘weekend-free’ media formulae such as StemFlex have reverted to using albumin and likely contain heparin, both of which are not chemically defined, we also assessed the function of these components in this assay and found that both improved the stability of FGF2-G3 (**Figure 4E**).

With the understanding that B8 supports hiPSC growth across a variety of sub-optimal conditions (**Figure 4D**), we established the suitability of this formula to skip days of media change.

We established a matrix of media change days both with and without thiazovivin (**Figure 5A**) and showed that daily B8 media changes (top row) was surprisingly the least suitable for growth rate. B8T treatment without media changes was the least effective of the thiazovivin-containing protocols (bottom row), whereas B8T followed by B8 (dark grey bar) was a suitable compromise between growth rate and extended exposure to thiazovivin. With the knowledge of the influence of various media change-skipping timelines, we devised a 7-day schedule consisting of passaging cells every 3.5 days that would allow for the skipping of media changes on the weekends, a major caveat of current hiPSC culture protocols (**Figures 5B** and **5C**). Our data demonstrated that a 3.5-day schedule with medium exchange after the first 24 h was suitable long-term, whereas no media exchange (i.e. passage only) was not suitable (**Figure 5D**). In addition, supplementation of the media with 0.5 mg ml<sup>-1</sup> of albumin did not rescue this deficit (**Figure 5D**). Further experiments with various doses of albumin or heparin further confirmed that these do not have an additive effect in B8 (**Figure 5E**). One of the major caveats of skipping media changes is that differentiation efficiency and reproducibility is diminished. We used our existing cardiac (Burrige et al., 2014), endothelial (Patsch et al., 2015), and epithelial differentiation (Li et al., 2015; Qu et al., 2016) protocols to demonstrate that B8 supported differentiation to a similarly high level with either daily media change or our 7-day protocol (**Figures 5F** and **5G**).

## Discussion

The hiPSC field predominantly utilizes two hiPSC culture media, the commercial mTeSR1 and Essential-8. Despite the formulae for these media being available to researchers, the complexity of media compounding and cost of growth factors required have made this unappealing. These two media, along with five other published hiPSC culture media formulae, have much in common due to their shared history (**Figure S1A**). Despite this, there are many media components that have not

had their concentration optimized or necessity demonstrated. In many cases, especially the formulation of TeSR, optimization experiments were discussed yet no data were provided. In the experiments here we found that only five components were truly essential for hiPSC culture: insulin, sodium selenite, FGF2, DMEM/F12, (**Figure 1**) and importance of a fifth component TGF $\beta$ 1 was only evident in the long-term assay (**Figures 1H, 3I, and S3A**). The other three components, ascorbic acid 2-phosphate, transferrin, and NRG1, are dispensable for hiPSC growth, although their removal results in a reduced growth rate.

During the development of this assay platform, we found that precise measurement of relative growth was a suitable surrogate for metrics of the pluripotent state (such as *NANOG* expression). When cells began to spontaneously differentiate, such as when TGF $\beta$ 1 is omitted from the formula, the resulting slowing of growth was easily detectable. We noted a number of surprising results during this optimization. For example, we could not find a positive or negative effect of the addition of albumin (**Figure 2D**) despite it being a common constituent of many academic and commercial media formulae. We propose that high levels of ascorbic acid in our formula may have eliminated some of the need for the antioxidant role of albumin. We found that Activin A was not suitable either with or without TGF $\beta$ 1 (**Figure 3H and S3B**) despite its inclusion in a variety of other formulae. We do show that at very low doses Activin A could support growth, albeit to a lesser extent than TGF $\beta$ 1. In some media formulae, such as hESF9T, there is a positive correlation between higher levels of TGF $\beta$ 1 (up to 10 ng ml<sup>-1</sup>) and expression of *NANOG* (Yamasaki et al., 2014) while others have found only minimal differences above 0.1 ng ml<sup>-1</sup> (Frank et al., 2012). Similarly, it was shown that higher levels of HSA correlated with higher levels of *POU5F1*, *SOX2*, and *NANOG* (Frank et al., 2012) yet albumin-free formulae have been used extensively without issue. One of our major efforts during the development of B8 was the minimization of media costs.

In our previous E8-based formula, the growth factors FGF2 and TGF $\beta$ 1 represented more than 80% of the total medium costs and we found that this could be much higher if laboratories could not negotiate discounts from commercial recombinant protein suppliers (**Figure S5A**). The generation of recombinant proteins in-house, although daunting, was highly simplified by using three commercial products: MagicMedia for *E. coli* growth, B-PER for lysis, and Ni-NTA spin columns for purification. Combined, these eliminate much of the complexity for recombinant protein production, including the need for HPLC or FPLC. Each of these components could easily be replaced by more cost-effective procedures such as inducing protein expression using IPTG, making lysis buffers, or using higher-throughput columns, albeit with greater complexity. Our optimization of the plasmids and generation of thioredoxin fusion proteins where necessary eliminates much of the complexity associated with inclusion bodies and the resulting refolding processes otherwise required. A typical 1 liter *E. coli* culture, which requires two days and basic laboratory skills, will usually provide 80 mg of FGF2-G3, enough for 800 liters of B8. Similarly, a 500 ml culture of TGF $\beta$ 3 or NRG1 will commonly provide enough protein years of work (~800,000 liters of B8 media). This optimization leaves insulin and transferrin as the major remaining costs. We show that the concentrations of these components can be reduced by 75% without a substantial impact on growth rate (both at 5  $\mu\text{g ml}^{-1}$ ) (**Figure 3B** and **3D**) and based on these savings, have developed a formulation of B8 optimized for low-cost (**Figure S5B** and **S5C**). The difference between growth rate of hiPSC in either formula is likely undetectable in normal culture.

The final major cost is the basal media DMEM/F12 representing ~75% of the B8 formula (**Figure S5A**). It is simple to generate DMEM/F12 from powder to reduce costs, although the requirement for suitable water quality and filter sterilization adds complexity to the media making process and therefore may not be appropriate for all but the highest usage labs. DMEM/F12 is a

combination of 52 amino acids, vitamins, inorganic salts, and other components derived from DMEM, a high nutrient (amino acid and vitamin) concentration media, originally optimized for fibroblast growth, and F12, a rich and complex fatty acid-containing media optimized for CHO cells to generate a complex ‘catch-all’ formula. Few experiments have been completed to compare alternatives to DMEM/F12 for hiPSC culture, indeed, Chen *et al.* showed comparable results between DMEM/F12 and the comparatively simple MEM $\alpha$ , suggesting that there is much to learn in this respect. hiPSC culture without daily media changes introduces a number of potential caveats, for example, we know that the L-glutamine in the medium is unstable at 37 °C and that the concentration is reduced by about a third over four days. We also know that cells are producing ammonia, reducing the pH of the media, although this buffered partially by the HEPES and sodium bicarbonate. Finally, hiPSCs release autocrine or paracrine factors into the media that may induce differentiation and the increase in these factors over time has not been decoupled from the use of nutrients and production of metabolic waste. We chose not to maintain exposure to Rho-associated kinase (ROCK1/2) inhibitors as there exists data suggesting that this induces epithelial-to-mesenchymal transition (Maldonado et al., 2016). Furthermore, ROCK inhibitors have a wide-range of off-target effects (Andrews et al., 2010). These issues may result in undesired effects although this remains to be validated experimentally and formulations do exist that maintain constant ROCK1/2 inhibitor exposure (Tsutsui et al., 2011).

As hiPSC projects become larger and move beyond proof-of-principle experiments, the labor required to maintain cells becomes burdensome, especially the need for daily media changes 7-days a week. Here we show that our B8 formula is well-suited to weekend-free schedules. A major issue with some commercial media is that although a weekend-free schedule is feasible, growth of hiPSCs is considerably slower and it is recommended to grow cells as low-density colonies. These low-density colonies are not compatible with subsequent monolayer

differentiation protocols, as have become commonplace with the majority of lineages. The optimization of B8 specifically for fast monolayer growth, along with the incorporation of thermostable FGF2-G3, overcomes many of these issues while maintaining compatibility with common differentiation protocols and has become standard practice within our laboratory.

## Experimental Procedures

### Human Induced Pluripotent Cell Culture

All pluripotent and reprogramming cell cultures were maintained at 37 °C in Heracell VIOS 160i direct heat humidified incubators (Thermo Scientific) with 5% CO<sub>2</sub> and 5% O<sub>2</sub>. Differentiation cultures were maintained at 5% CO<sub>2</sub> and atmospheric (~21%) O<sub>2</sub>. All cultures (pluripotent and differentiation) were maintained with 2 ml medium per 9.6 cm<sup>2</sup> of surface area or equivalent. All media was used at 4 °C and was not warmed to 37 °C before adding to cells due to concerns of the thermostability of the FGF2 (Chen et al., 2012). We have found no detectable effects on cell growth from using cold media. All cultures were routinely tested for mycoplasma using a MycoAlert PLUS Kit (Lonza) and a 384-well Varioskan LUX (Thermo Scientific) plate reader. E8 medium was made in-house as previously described (Burrige et al., 2015; Chen et al., 2011) and consisted of DMEM/F12 (Corning, 10-092-CM), 20 µg ml<sup>-1</sup> *E. coli*-derived recombinant human insulin (Gibco, A11382IJ), 64 µg ml<sup>-1</sup> L -ascorbic acid 2-phosphate trisodium salt (Wako, 321-44823), 10 µg ml<sup>-1</sup> *Oryza sativa*-derived recombinant human transferrin (Optiferrin, InVitria, 777TRF029-10G.), 14 ng ml<sup>-1</sup> sodium selenite (Sigma, S5261), 100 ng ml<sup>-1</sup> recombinant human FGF2-K128N (made in-house, see below), 2 ng ml<sup>-1</sup> recombinant human TGFβ1 (112 amino acid, HEK293-derived, Peprotech, 100-21). Cells were routinely maintained in E8 medium on 1:800 diluted growth factor reduced Matrigel (see below). E8 was supplemented with 10 µM Y27632 dihydrochloride (LC Labs, Y-5301), hereafter referred to as E8Y, for the first 24 h after passage. For standard culture, cells were passaged at a ratio of 1:20 every 4 days using 0.5 mM EDTA (Invitrogen UltraPure) in DPBS (without Ca<sup>2+</sup> and Mg<sup>2+</sup>, Corning), after achieving ~70-80% confluence. Cell lines were used between passages 20 and 100. Other media components tested were: Human Long R3 IGF1 (Sigma, 91590C), thiazovivin (LC Labs, T-9753), recombinant



human TGF $\beta$ 3 (Cell Guidance Systems, GFH109), sodium bicarbonate (Sigma), NEAA (Gibco), CD Lipids (Gibco), fatty acid-free albumin (GenDEPOT, A0100). pH was adjusted with 10N HCl or 1N NaOH (both from Sigma) and measured using a SevenCompact pH meter (MettlerToledo). Osmolarity was adjusted with sodium chloride (Sigma) or cell culture water (Corning) and measured with an osmometer (Advanced Instruments).

### **Matrigel Optimization**

Our standard condition throughout was 2 ml of 1:800 reduced growth factor Matrigel (Corning, 354230) diluted in 2 ml of DMEM (Corning, 10-017-CV) per well of 6-well plate or equivalent. Also tested were Geltrex (Gibco) and Cultrex (Trevigen). Plates were made and kept in incubators at 37 °C for up to one month.

### **FGF2-K128N Generation**

The full length (154 amino acid) FGF2 sequence: AAGSITTLP ALPEDGGSGA FPPGHFKDPK RLYCKNGGFF LRIHPDGRVD GVREKSDPHI KLQLQAEERG VVSIKGVCAN RYLAMKEDGR LLASKCVTDE CFFFERLESN NYNTYRSRKY TSWYVAL**K**RRT GQYKLGSKTG PGQKAILFLP MSAKS with a K128N substitution (in bold/underlined) was codon optimized for *E. coli* with the addition of a *Bam*HI site at the start (5') of the sequence and an *Eco*RI site at the end (3'). This sequence was synthesized on a BioXp 3200 (Synthetic Genomics). The insert was then digested with *Bam*HI and *Eco*RI (Anza, Invitrogen) and ligated with T4 DNA ligase (Anza) in to a pET-28a expression vector (Novagen/MilliporeSigma) and cloned in to One Shot BL21 Star (DE3) chemically competent *E. coli* (Invitrogen). *E. coli* were stored in 25% glycerol (Ultrapure, Invitrogen) at -80 °C. A starter cultured was prepared by inoculating 10 ml of Terrific Broth (Fisher BioReagents) supplemented with 50  $\mu$ g ml<sup>-1</sup> kanamycin

sulfate (Fisher BioReagents) in a bacterial tube (Corning Falcon) and incubated in an Innova-44 Incubator-Shaker (New Brunswick) at 220 rpm overnight at 30 °C (for FGF2 or TGFβ3) or 37 °C (for NRG1). Protein expression was performed using a 2800 ml baffled shaker flask (Fisherbrand, BBV2800) as follows: The 5 ml of starter culture was added to 500 ml of MagicMedia (K6815, Invitrogen), supplemented with 50 µg/ml kanamycin sulfate and incubated as above for 24 h at 30 °C (for FGF2 or TGFβ3) or 37 °C (for NRG1). The culture was harvested into 2 × 250 ml centrifuge bottles (Nalgene, 3120-0250) and centrifuged in an Optimia XPN-100 ultra centrifuge (Beckman Coulter) with a SW 32 Ti rotor at 5,000 × g for 20 min at 4 °C. Supernatant was carefully poured off and pellets were weighed and stored at -80 °C for downstream processing. Cells pellets were resuspended in B-PER lysis buffer (Thermo Scientific, 78248) using 5 ml of B-PER Complete Reagent per gram of bacterial cell pellet. Cells were incubated for 15 minutes at RT with gentle rocking. The bottles containing the lysates were then centrifuged in an ultracentrifuge at 16,000 × g for 20 min at 4 °C. Supernatants were collected and the cell debris was discarded. Purification was completed using a 3 ml HisPur Ni-NTA Spin Purification Kit (Thermo Scientific, 88229) following the manufacturers recommendations. To enhance the protein binding efficiency to the resin bed, the sample was incubated for 30 min at 4 °C. Four elutes were collected, one every 10 min. The columns were reused following the manufacturer's regeneration protocol. The protein concentration was evaluated using Quant-iT Qubit Protein Assay Kit (Invitrogen, Q3321) on a Qubit 3 fluorometer. The 6xHis tag was not cleaved as it has been previously demonstrated to not interfere with the FGF2 function (Soleyman et al., 2016). A standard 1 liter culture produced 80 mg of FGF2.

### **FGF2-G3 Generation**

154 amino acid sequence: AAGSITTLP ALPEDGGSGA FPPGHFKDPK **L**LYCKNGGFF  
LRIHPDGRVD **G****T****R****D****K**S**D****P****F****I** KLQLQAEERG VVSIKGVCAN RYLAMKEDGR  
**L****Y****A****I****K****N**VTDE CFFFERLE**E**N NYNTYRSRKY **P**SWYVALKRT GQYKLGSKTG  
PGQKAILFLP MSAKS with R31L, V52T, E54D, H59F, L92Y, S94I, C96N, S109E, and T121P  
substitutions (in bold) was codon optimized for *E. coli* was generated as above. FGF1-4X was  
similarly generated.

### **TGFβ3 Generation**

112 amino acid sequence: ALDTNYCFRN LEENCCVRPL YIDFRQDLGW KVVHEPKGYY  
ANFCSGPCPY LRSADTTHST VLGLYNTLNP EASASPCCVP QDLEPLTILY  
YVGRTPKVEQ LSNMVVKSCK CS was codon optimized for *E. coli* and generated as above,  
ligated in to a pET-32a expression vector, and cloned in to One Shot BL21 Star (DE3). The use of  
pET-32a results in the production of a thioredoxin-TGFBβ3 fusion protein which prevents protein  
expression in inclusion bodies. It is not necessary to cleave the thioredoxin for TGFBβ3 to be  
active. TGFβ1, TGFβ1m (C77S), and TGFβ3m (C77S) were similarly generated.

### **NRG1 Generation**

65 amino acid sequence: SHLVKCAEKE KTFCVNGGEC FMVKDLSNPS RYLCKCPNEF  
TGDRQCQNYVM ASFYKHLGIE FMEAE, which is a truncated version of NRG1 containing just  
the EGF domain, was codon optimized for *E. coli* and generated as above, ligated in to a pET-32a  
expression vector, and cloned in to One Shot BL21 Star (DE3). The use of pET-32a results in the  
production of a thioredoxin-NRG1 fusion protein which prevents protein expression in inclusion  
bodies. It was found necessary to cleave the thioredoxin using Thrombin CleanCleave Kit  
(MilliporeSigma), followed by repurification, keeping the supernatant.

### **Media Variable Optimization Protocol**

The hiPSC line 19-3 was dissociated with TrypLE (Gibco, 12604-013) for 3 min at 37 °C and cells were resuspended in DMEM/F12, transferred to a 15 ml conical tube (Falcon) and centrifuged at  $200 \times g$  for 3 min (Sorvall ST40). The pellet was resuspended in DMEM/F12, diluted to  $1 \times 10^5$  cells per ml and 10,000 cells were plated per well in Matrigel (1:800)-coated 12-well plates (Greiner) in the medium to be tested along with 2  $\mu$ M thiazovivin for the first 24 h. Media were changed daily and cells were grown for 6 days. This lower than normal seeding density was used to allow the discovery of factors only detectable under more extreme conditions and therefore provide data on the robustness to the formulation.

### **Western Blot**

Stock lysis buffer was prepared as 150 mM NaCl, 20 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, and 1% Triton X-100 and stored at 4 °C. Fresh complete lysis buffer was prepared with final concentration of 1 $\times$  Protease Inhibitor (Roche, 5892791001), 1 $\times$  Phosphatase Inhibitor Cocktail 2 (P5726, Sigma), 1 $\times$  Phosphatase Inhibitor Cocktail 3 (Sigma, P0044), 2 mM PMSF (Sigma, P7626), and 1% SDS Solution (Fisher Scientific, BP2436200). hiPSC were starved using B8 without FGF2 for 24 hours, then treated with media containing the corresponding FGF2 for 1 h. Media was then removed, and cells were washed once with DPBS, harvested with 0.5 mM EDTA in DPBS, and transferred into tubes. Samples were pelleted by centrifugation at  $500 \times g$  for 3 minutes and the supernatant was discarded. The pellet was resuspend in 150  $\mu$ l complete lysis buffer and incubated on ice for 30 min. Clear lysates were collected by centrifugation at  $10,000 \times g$  for 10 min at 4 °C. The protein concentration was measured with Qubit Protein Assay Kit (Invitrogen, Q33211) and Qubit 4 fluorometer. Lysates was stored in -80 °C before use. 10  $\mu$ g of

sample was prepared with NuPAGE LDS Sample Buffer (Invitrogen, B0007) and NuPAGE Reducing Agent (Invitrogen, B0009) according to the manufacturer's instructions and run on NuPAGE 10% Bis-Tris Gel (Invitrogen, NP0302BOX) and Mini Gel Tank system (Invitrogen, A25977) with Bolt MES SDS Running Buffer (Invitrogen, B000202) at 100 V for 1 h. SeeBlue Plus2 Pre-Stained Protein Standard (Invitrogen, LC5925) was used as a ladder. The gel was then transferred in Mini Trans-Blot Cell system (Bio-Rad, 1703930) on to a PVDF transfer membrane (Thermo Scientific, 88518) at 240 mA for 1 h and 30 min. The membrane was blocked with 5% BSA (GenDEPOT, A0100) in 1% TBST (Fisher Scientific, BP2471-1, BP337-100) overnight. All the primary and secondary antibodies were diluted with 5% BSA in 1% TBST. Washes were done as a short rinse followed by 5 long washes for 5 min each. Both primary (Cell Signaling Technology, 9101, 9102) and secondary antibodies (92632211, LI-COR) were incubated for 1 h at RT. The blot was imaged with Odyssey CLx (LI-COR). The blot was stripped with Restore PLUS Western Blot Stripping Buffer (Thermo Scientific, 46430) for 15 min at RT, rinsed with 1% TBST and reblocked with 5% BSA for 30 min.

### **Human Induced Pluripotent Stem Cell Derivation**

Protocols were approved by the Northwestern University Institutional Review Boards. With informed written consent, ~9 ml of peripheral blood was taken from each volunteer and stored at 4 °C, samples were transferred to Leucosep tubes (Greiner) filled with Histopaque-1077 (Sigma).  $1 \times 10^6$  isolated peripheral blood mononuclear cells (PMBC) were grown in 24-well tissue culture-treated plates (Greiner) in 2 ml of SFEM II (Stem Cell Technologies) supplemented with 10 ng ml<sup>-1</sup> IL3, 50 ng ml<sup>-1</sup> SCF (KITLG), 40 ng ml<sup>-1</sup> IGF1 (all Peprotech), 2 U ml<sup>-1</sup> EPO (Calbiochem), 1 μM dexamethasone (Sigma) (Chou et al., 2015). 50% medium was changed every other day. After 12 days of growth,  $6 \times 10^4$  cells were transferred to a well of a 24-well plate in 500 μL of

SFEM II with growth factors supplemented with CytoTune-iPS 2.0 Sendai Reprogramming Kit viral particle factors (Gibco) (Fujie et al., 2014; Fusaki et al., 2009) diluted to 5% (1:20) of the manufacturer's recommendations. Cells were treated with 3.5  $\mu$ L, 3.5  $\mu$ l, and 2.2  $\mu$ l of hKOS ( $0.85 \times 10^8$  CIU  $\text{ml}^{-1}$ ), hMYC ( $0.85 \times 10^8$  CIU  $\text{ml}^{-1}$ ), and hKLF4 ( $0.82 \times 10^8$  CIU  $\text{ml}^{-1}$ ), respectively at MOI of 5:5:3 (KOS:MYC:KLF4). 100% media was changed after 24 h by centrifugation ( $300 \times g$ , 4 min) to 2 ml fresh SFEM II with growth factors, and cells were transferred to one well of a 6-well plate (Greiner) coated with 1:800 Matrigel. 50% medium was changed gently every other day. On day 8 after transduction, 100% of medium was changed to B8 medium. Medium was changed every day. At day 17 individual colonies were picked into a Matrigel-coated 12-well plate (one colony per well).

### **Pluripotent Cell Flow Cytometry**

hiPSCs were dissociated with TrypLE Express (Gibco) for 3 min at 37 °C and  $1 \times 10^6$  cells were transferred to flow cytometry tubes (Falcon, 352008). Cells were stained in 0.5% fatty acid-free albumin in DPBS using 1:20 mouse IgG<sub>3</sub> SSEA4-488 clone MC-813-70 (R&D Systems, FAB1435F, lot YKM0409121) and 1:20 mouse IgM TRA-1-60-488 clone TRA-1-60 (BD Biosciences, 560173, lot 5261629) for 30 min on ice then washed. Isotype controls mouse IgG<sub>3</sub>-488 clone J606 (BD Biosciences, 563636, lot 7128849) and mouse IgM-488 clone G155-228 (BD Bioscience, 562409, lot 7128848) were used to establish gating. All cells were analyzed using a CytoFLEX (Beckman Coulter) with CytExpert 2.2 software.

### **Immunofluorescent Staining**

hiPSCs were dissociated with 0.5 mM EDTA and plated onto 1:800 Matrigel-treated Nunc Lab-Tek II 8-chamber slides in B8 medium for three days (B8T for the first 24 h). Cells were fixed,

permeabilized, and stained for OCT4, SSEA4, SOX2, TRA-1-60 with PSC 4-Marker Immunocytochemistry Kit (Life Technologies, A24881, lot 1610720) according to the manufacturer's instructions. Cells were washed three times and mounted with ProLong Diamond Antifade Mountant with DAPI (Invitrogen). Slides were imaged with a Ti-E inverted fluorescent microscope (Nikon Instruments) and a Zyla sCMOS camera (Andor) using NIS-Elements 4.4 Advanced software.

### **Population Doubling Level Assessment**

Population doubling level (PDL) was calculated according to the following formula:

$$\text{PDL} = 3.32[\log_{10}(n/n_0)]$$

Where  $n$  = cell number and  $n_0$  = number of cells seeded

### **Cardiac Differentiation**

Differentiation into cardiomyocytes was performed according to previously described protocol with slight modifications (Burrige et al., 2015; Burrige et al., 2014). Briefly, hiPSCs were split at 1:20 ratios using 0.5 mM EDTA as above and grown in B8 medium for 4 days reaching ~75% confluence. At the start of differentiation (day 0), B8 medium was changed to CDM3 (chemically defined medium, three components) (Burrige et al., 2014), consisting of RPMI 1640 (Corning, 10-040-CM), 500  $\mu\text{g ml}^{-1}$  fatty acid-free bovine serum albumin (GenDEPOT), and 200  $\mu\text{g ml}^{-1}$  L-ascorbic acid 2-phosphate (Wako). For the first 24 h, CDM3 medium was supplemented with 6  $\mu\text{M}$  of glycogen synthase kinase 3- $\beta$  inhibitor CHIR99021 (LC Labs, C-6556). On day 1, medium was changed to CDM3 and on day 2 medium was changed to CDM3 supplemented with 2  $\mu\text{M}$  of the Wnt inhibitor Wnt-C59 (Biorbyt, orb181132). Medium was then changed on day 4 and every other day for CDM3. Contracting cells were noted from day 7. On day 14 of differentiation,

cardiomyocytes were dissociated using DPBS for 20 min at 37 °C followed by 1:200 Liberase TH (Roche) diluted in DPBS for 20 min at 37 °C, centrifuged at 300 g for 5 min, and filtered through a 100 µm cell strainer (Falcon).

### **Endothelial Differentiation**

hiPSCs were grown to approximately 50-70% confluent and differentiated according to an adapted version of a protocol previously described (Patsch et al., 2015). On day 5 of differentiation, endothelial cells were dissociated with Accutase (Gibco) for 5 min at 37 °C, centrifuged at 300 g for 5 min, and analyzed.

### **Epithelial Differentiation**

hiPSCs were split at 1:20 ratios using 0.5 mM EDTA as above and grown in B8T medium for 1 day reaching ~15% confluence at the start of differentiation. Surface ectoderm differentiation was performed according to an adapted version of previously described protocols (Li et al., 2015; Qu et al., 2016). On day 4 of differentiation, epithelial cells were dissociated with Accutase (Gibco) for 5 min at 37 °C, centrifuged at 300 g for 5 min, and analyzed.

### **Differentiated Cell Flow Cytometry**

Cardiomyocytes were dissociated with Liberase TH as described above, transferred to flow cytometry tubes and fixed with 4% PFA (Electron Microscopy Services) for 15 min at RT, and then permeabilized with 0.1% Triton X-100 (Fisher BioReagents) for 15 min at RT, washed once with DPBS, and stained using 1:33 mouse monoclonal IgG<sub>1</sub> TNNT2-647 clone 13-11 (BD Biosciences, 565744, lot 7248637) for 30 min at RT and washed again. Isotype control mouse IgG<sub>1</sub>-647 clone MOPC-21 (BD Biosciences, 565571, lot 8107668) was used to establish gating.



Endothelial cells were dissociated with Accutase as described above, transferred to flow cytometry tubes and stained with 1:100 mouse IgG2a CD31-647 clone M89D3 (BD Bioscience, 558094, lot 8145771) for 30 min on ice then washed once with DPBS. Isotype control mouse IgG<sub>1</sub>-647 clone MOPC-21 (BD Biosciences, 565571, lot 8107668) was used to establish gating. Epithelial cells were dissociated with Accutase as described above, transferred to flow cytometry tubes, fixed with 4% PFA (Electron Microscopy Services) for 10 min at RT, and then permeabilized with 0.1% saponin (Sigma) in DPBS for 15 min at RT. Cells were washed once in wash buffer (DPBS with 5% FBS, 0.1% NaN<sub>3</sub>, 0.1% saponin), stained with 1:200 mouse IgG<sub>1</sub> KRT18-647 clone DA-7 (BioLegend, 628404, lot. B208126) for 30 min at RT, then washed twice with wash buffer. Isotype control mouse IgG<sub>1</sub>-647 clone MOPC-21 (BD Biosciences, 565571, lot 8107668) was used to establish gating. All cells were analyzed using a CytoFLEX (Beckman Coulter) with CytExpert 2.2 software.

## Statistical Methods

Data were analyzed in Excel or R and graphed in GraphPad Prism 8. Detailed statistical information is included in the corresponding figure legends. Data were presented as mean ± SEM. Comparisons were conducted via an unpaired two-tailed Student's t-test with significant differences defined as  $P < 0.05$  (\*),  $P < 0.01$  (\*\*),  $P < 0.005$  (\*\*\*), and  $P < 0.0001$  (\*\*\*\*). No statistical methods were used to predetermine sample size. The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment.

## Acknowledgments

This work was supported by NIH NCI grant R01 CA220002, American Heart Association Transformational Project Award 18TPA34230105, a Dixon Foundation Translational Research Grants Innovation Award (P.W.B.) and the Fondation Leducq (P.W.B., A.L.G).

### **Author Contributions**

P.W.B. conceived and supervised the project. H-H.K. completed most experiments, along with K.A.F., E.A.P., C.J.W., M.V.O, M.J., M.R.-T., H.-H.K., M.B., and T.M. Recombinant protein production was completed by X.G. and plasmid generation by J.-M.D. C.E. provided technical support and A.L.G provided recombinant DNA construction. P.W.B. wrote the paper. All authors approved the manuscript.

### **Declaration of Interests**

The authors declare no competing interests.

## References

Amit, M., Shariki, C., Margulets, V., and Itskovitz-Eldor, J. (2004). Feeder layer- and serum-free culture of human embryonic stem cells. *Biol Reprod* 70, 837-845.

Andrews, P.D., Becroft, M., Aspegren, A., Gilmour, J., James, M.J., McRae, S., Kime, R., Allcock, R.W., Abraham, A., Jiang, Z., *et al.* (2010). High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. *Biochem J* 432, 21-33.

Beers, J., Gulbranson, D.R., George, N., Siniscalchi, L.I., Jones, J., Thomson, J.A., and Chen, G. (2012). Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions. *Nat Protoc* 7, 2029-2040.

Besser, D. (2004). Expression of nodal, lefty-a, and lefty-B in undifferentiated human embryonic stem cells requires activation of Smad2/3. *J Biol Chem* 279, 45076-45084.

Braam, S.R., Zeinstra, L., Litjens, S., Ward-van Oostwaard, D., van den Brink, S., van Laake, L., Lebrin, F., Kats, P., Hochstenbach, R., Passier, R., *et al.* (2008). Recombinant vitronectin is a functionally defined substrate that supports human embryonic stem cell self-renewal via  $\alpha$ 5 $\beta$ 1 integrin. *Stem Cells* 26, 2257-2265.

Breckwoldt, K., Letuffe-Breniere, D., Mannhardt, I., Schulze, T., Ulmer, B., Werner, T., Benzin, A., Klampe, B., Reinsch, M.C., Laufer, S., *et al.* (2017). Differentiation of cardiomyocytes and generation of human engineered heart tissue. *Nat Protoc* 12, 1177-1197.

Burridge, P.W., Holmstrom, A., and Wu, J.C. (2015). Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. *Curr Protoc Hum Genet* 87, 21.23.1-15.

Burridge, P.W., Matsa, E., Shukla, P., Lin, Z.C., Churko, J.M., Ebert, A.D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N.M., *et al.* (2014). Chemically defined generation of human cardiomyocytes. *Nat Methods* 11, 855-860.

Burton, P., Adams, D.R., Abraham, A., Allcock, R.W., Jiang, Z., McCahill, A., Gilmour, J., McAbney, J., Kane, N.M., Baillie, G.S., *et al.* (2010). Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. *Biochem Soc Trans* 38, 1058-1061.

Chen, G., Gulbranson, D.R., Hou, Z., Bolin, J.M., Ruotti, V., Probasco, M.D., Smuga-Otto, K., Howden, S.E., Diol, N.R., Propson, N.E., *et al.* (2011). Chemically defined conditions for human iPSC derivation and culture. *Nat Methods* 8, 424-429.

Chen, G., Gulbranson, D.R., Yu, P., Hou, Z., and Thomson, J.A. (2012). Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells. *Stem Cells* 30, 623-630.

Chou, B.K., Gu, H., Gao, Y., Dowey, S.N., Wang, Y., Shi, J., Li, Y., Ye, Z., Cheng, T., and Cheng, L. (2015). A facile method to establish human induced pluripotent stem cells from adult blood cells under feeder-free and xeno-free culture conditions: a clinically compliant approach. *Stem Cells Transl Med* 4, 320-332.

Chou, B.K., Mali, P., Huang, X., Ye, Z., Dowey, S.N., Resar, L.M., Zou, C., Zhang, Y.A., Tong, J., and Cheng, L. (2011). Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. *Cell Res* 21, 518-529.

Desbordes, S.C., Placantonakis, D.G., Ciro, A., Socci, N.D., Lee, G., Djaballah, H., and Studer, L. (2008). High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. *Cell Stem Cell* 2, 602-612.

Dvorak, P., Bednar, D., Vanacek, P., Balek, L., Eiselleova, L., Stepankova, V., Sebestova, E., Kunova Bosakova, M., Konecna, Z., Mazurenko, S., *et al.* (2018). Computer-assisted engineering of hyperstable fibroblast growth factor 2. *Biotechnol Bioeng* 115, 850-862.

Eminli, S., Foudi, A., Stadtfeld, M., Maherali, N., Ahfeldt, T., Mostoslavsky, G., Hock, H., and Hochedlinger, K. (2009). Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. *Nat Genet* 41, 968-976.

Forristal, C.E., Wright, K.L., Hanley, N.A., Oreffo, R.O., and Houghton, F.D. (2010). Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. *Reproduction* 139, 85-97.

Frank, S., Zhang, M., Scholer, H.R., and Greber, B. (2012). Small molecule-assisted, line-independent maintenance of human pluripotent stem cells in defined conditions. *PLoS One* 7, e41958.

Fujie, Y., Fusaki, N., Katayama, T., Hamasaki, M., Soejima, Y., Soga, M., Ban, H., Hasegawa, M., Yamashita, S., Kimura, S., *et al.* (2014). New type of Sendai virus vector provides transgene-free iPS cells derived from chimpanzee blood. *PLoS One* 9, e113052.

Furue, M.K., Na, J., Jackson, J.P., Okamoto, T., Jones, M., Baker, D., Hata, R., Moore, H.D., Sato, J.D., and Andrews, P.W. (2008). Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. *Proc Natl Acad Sci U S A* 105, 13409-13414.

Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., and Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci* 85, 348-362.

Hannan, N.R., Segeritz, C.P., Touboul, T., and Vallier, L. (2013). Production of hepatocyte-like cells from human pluripotent stem cells. *Nat Protoc* 8, 430-437.

Huang, T., Schor, S.L., and Hinck, A.P. (2014). Biological activity differences between TGF-beta1 and TGF-beta3 correlate with differences in the rigidity and arrangement of their component monomers. *Biochemistry* 53, 5737-5749.

Hughes, C.S., Postovit, L.M., and Lajoie, G.A. (2010). Matrigel: a complex protein mixture required for optimal growth of cell culture. *Proteomics* 10, 1886-1890.

Kim, Y.V., Gasparian, M.E., Bocharov, E.V., Chertkova, R.V., Tkach, E.N., Dolgikh, D.A., and Kirpichnikov, M.P. (2015). New strategy for high-level expression and purification of biologically active monomeric TGF-beta1/C77S in *Escherichia coli*. *Mol Biotechnol* 57, 160-171.

Kumagai, H., Suemori, H., Uesugi, M., Nakatsuji, N., and Kawase, E. (2013). Identification of small molecules that promote human embryonic stem cell self-renewal. *Biochem Biophys Res Commun* 434, 710-716.

Lawitts, J.A., and Biggers, J.D. (1992). Joint effects of sodium chloride, glutamine, and glucose in mouse preimplantation embryo culture media. *Mol Reprod Dev* 31, 189-194.

Li, L., Song, L., Liu, C., Chen, J., Peng, G., Wang, R., Liu, P., Tang, K., Rossant, J., and Jing, N. (2015). Ectodermal progenitors derived from epiblast stem cells by inhibition of Nodal signaling. *J Mol Cell Biol* 7, 455-465.

Liu, W., Ren, Z., Lu, K., Song, C., Cheung, E.C.W., Zhou, Z., and Chen, G. (2018). The Suppression of Medium Acidosis Improves the Maintenance and Differentiation of Human Pluripotent Stem Cells at High Density in Defined Cell Culture Medium. *Int J Biol Sci* 14, 485-496.

Ludwig, T., and Thomson, J.A. (2007). Defined, feeder-independent medium for human embryonic stem cell culture. *Curr Protoc Stem Cell Biol* Chapter 1, Unit 1C 2.

Ludwig, T.E., Bergendahl, V., Levenstein, M.E., Yu, J., Probasco, M.D., and Thomson, J.A. (2006a). Feeder-independent culture of human embryonic stem cells. *Nat Methods* 3, 637-646.

Ludwig, T.E., Levenstein, M.E., Jones, J.M., Berggren, W.T., Mitchen, E.R., Frane, J.L., Crandall, L.J., Daigh, C.A., Conard, K.R., Piekarczyk, M.S., *et al.* (2006b). Derivation of human embryonic stem cells in defined conditions. *Nat Biotechnol* 24, 185-187.

Maldonado, M., Luu, R.J., Ramos, M.E., and Nam, J. (2016). ROCK inhibitor primes human induced pluripotent stem cells to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation. *Stem Cell Res* 17, 222-227.

Marinho, P.A., Chailangkarn, T., and Muotri, A.R. (2015). Systematic optimization of human pluripotent stem cells media using Design of Experiments. *Sci Rep* 5, 9834.

Melkounian, Z., Weber, J.L., Weber, D.M., Fadeev, A.G., Zhou, Y., Dolley-Sonneville, P., Yang, J., Qiu, L., Priest, C.A., Shogbon, C., *et al.* (2010). Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. *Nat Biotechnol* 28, 606-610.

Narva, E., Pursiheimo, J.P., Laiho, A., Rahkonen, N., Emani, M.R., Viitala, M., Laurila, K., Sahla, R., Lund, R., Lahdesmaki, H., *et al.* (2013). Continuous hypoxic culturing of human embryonic stem cells enhances SSEA-3 and MYC levels. *PLoS One* 8, e78847.

Patsch, C., Challet-Meylan, L., Thoma, E.C., Urich, E., Heckel, T., O'Sullivan, J.F., Grainger, S.J., Kapp, F.G., Sun, L., Christensen, K., *et al.* (2015). Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. *Nat Cell Biol* 17, 994-1003.

Piccini, I., Rao, J., Seebohm, G., and Greber, B. (2015). Human pluripotent stem cell-derived cardiomyocytes: Genome-wide expression profiling of long-term in vitro maturation in comparison to human heart tissue. *Genom Data* 4, 69-72.

Prowse, A.B., Doran, M.R., Cooper-White, J.J., Chong, F., Munro, T.P., Fitzpatrick, J., Chung, T.L., Haylock, D.N., Gray, P.P., and Wolvetang, E.J. (2010). Long term culture of human embryonic stem cells on recombinant vitronectin in ascorbate free media. *Biomaterials* 31, 8281-8288.

Qu, Y., Zhou, B., Yang, W., Han, B., Yu-Rice, Y., Gao, B., Johnson, J., Svendsen, C.N., Freeman, M.R., Giuliano, A.E., *et al.* (2016). Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs. *Sci Rep* 6, 32007.

Rodin, S., Antonsson, L., Niaudet, C., Simonson, O.E., Salmela, E., Hansson, E.M., Domogatskaya, A., Xiao, Z., Damdimopoulou, P., Sheikhi, M., *et al.* (2014). Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin matrix in defined and xeno-free environment. *Nat Commun* 5, 3195.

Rodin, S., Domogatskaya, A., Strom, S., Hansson, E.M., Chien, K.R., Inzunza, J., Hovatta, O., and Tryggvason, K. (2010). Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. *Nat Biotechnol* 28, 611-615.

Sato, N., Sanjuan, I.M., Heke, M., Uchida, M., Naef, F., and Brivanlou, A.H. (2003). Molecular signature of human embryonic stem cells and its comparison with the mouse. *Dev Biol* 260, 404-413.

Singh, A.M., Reynolds, D., Cliff, T., Ohtsuka, S., Mattheyses, A.L., Sun, Y., Menendez, L., Kulik, M., and Dalton, S. (2012). Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. *Cell Stem Cell* 10, 312-326.

Soleyman, M.R., Khalili, M., Khansarinejad, B., and Baazm, M. (2016). High-level Expression and Purification of Active Human FGF-2 in *Escherichia coli* by Codon and Culture Condition Optimization. *Iran Red Crescent Med J* 18, e21615.

Staerk, J., Dawlaty, M.M., Gao, Q., Maetzel, D., Hanna, J., Sommer, C.A., Mostoslavsky, G., and Jaenisch, R. (2010). Reprogramming of human peripheral blood cells to induced pluripotent stem cells. *Cell Stem Cell* 7, 20-24.

Tan, H.K., Toh, C.X., Ma, D., Yang, B., Liu, T.M., Lu, J., Wong, C.W., Tan, T.K., Li, H., Syn, C., *et al.* (2014). Human finger-prick induced pluripotent stem cells facilitate the development of stem cell banking. *Stem Cells Transl Med* 3, 586-598.

Tsutsui, H., Valamehr, B., Hindoyan, A., Qiao, R., Ding, X., Guo, S., Witte, O.N., Liu, X., Ho, C.M., and Wu, H. (2011). An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. *Nat Commun* 2, 167.

Vallier, L., Alexander, M., and Pedersen, R.A. (2005). Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. *J Cell Sci* 118, 4495-4509.


Vallier, L., Touboul, T., Brown, S., Cho, C., Bilican, B., Alexander, M., Cedervall, J., Chandran, S., Ahrlund-Richter, L., Weber, A., *et al.* (2009). Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. *Stem Cells* 27, 2655-2666.

Wang, L., Schulz, T.C., Sherrer, E.S., Dauphin, D.S., Shin, S., Nelson, A.M., Ware, C.B., Zhan, M., Song, C.Z., Chen, X., *et al.* (2007). Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. *Blood* 110, 4111-4119.

Xu, C., Rosler, E., Jiang, J., Lebkowski, J.S., Gold, J.D., O'Sullivan, C., Delavan-Boorsma, K., Mok, M., Bronstein, A., and Carpenter, M.K. (2005). Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. *Stem Cells* 23, 315-323.


Yamasaki, S., Taguchi, Y., Shimamoto, A., Mukasa, H., Tahara, H., and Okamoto, T. (2014). Generation of human induced pluripotent stem (Ips) cells in serum- and feeder-free defined culture and TGF-Beta1 regulation of pluripotency. *PLoS One* 9, e87151.

Yasuda, S., Ikeda, T., Shahsavarani, H., Yoshida, N., Nayer, B., Hino, M., Vartak-Sharma, N., Suemori, H., and Hasegawa, K. (2018). Chemically defined and growth-factor-free culture system for the expansion and derivation of human pluripotent stem cells. *Nature Biomedical Engineering* 2, 173-182.




**Figure 1. Optimization of Basic Human Pluripotent Stem Cell Medium Constituents with a Short-Term Growth Assay.** Results are normalized to initial medium component concentrations shown with a dark gray bar, optimizations were completed using short-term 6-day growth assay. Optimized component concentrations shown with a diagonal hash. **(A)** Concentrations of initial media formula components. **(B)** Schematic of assay growth schedule. **(C)** Comparison of the effect of recombinant human IGF1 LR3 ( $n = 3$ ) and recombinant human insulin ( $n = 18-22$ ) concentrations on relative growth. **(D)** L-ascorbic acid 2-phosphate ( $n = 19-27$ ). **(E)** Transferrin ( $n = 2-20$ ). **(F)** Sodium selenite ( $n = 3-20$ ). **(G)** FGF2-K128N ( $n = 3-12$ ). **(H)** TGF $\beta$ 1 ( $n = 20-25$ ).  $n$  = full experimental replicates, unpaired Student's T-test, \* $P \leq 0.05$ , \*\* $P \leq 0.01$ , \*\*\* $P \leq 0.005$ , \*\*\*\* $P \leq 0.0001$ , n.s. = not significant.







**Figure 2. Optimization of Additional Human Pluripotent Stem Cell Medium Constituents in a Short-Term Assay.** E8 medium component concentrations are shown with a dark gray bar, optimizations were completed using a simple 6-day growth assay. Optimized component concentrations shown with a diagonal hash. **(A)** Comparison of the suitability of recombinant transferrin ( $10 \mu\text{g ml}^{-1}$ ) to support clonal growth with and without ROCK1/2 inhibition using Y27632 ( $10 \mu\text{M}$ ) during the first 24 h after passage ( $n = 3$ ). **(B)** Comparison of two common ROCK1/2 inhibitors only during first 24 h after passage on relative growth ( $n > 5$ ). **(C)** Comparison of the effect of the addition of non-essential amino acids (NEAA) and chemically defined lipids ( $n = 5$ ) on relative growth. **(D)** Fatty acid-free albumin ( $n = 4$ ). **(E)** Sodium bicarbonate ( $n = 5$ ). **(F)** pH ( $n = 9$ ). **(G)** Osmolarity ( $n = 8$ ). **(H)** FGF2-G3 ( $n = 3$ ).  $n$  = full experimental replicates, unpaired Student's T-test,  $*P \leq 0.05$ ,  $**P \leq 0.01$ ,  $***P \leq 0.005$ ,  $****P \leq 0.0001$ , n.s. = not significant.




**Figure 3. Optimization of B8 Medium Constituents with a Long-Term Growth Assay.** Results are normalized to initial medium component concentrations shown with a dark gray bar, optimizations were completed using long-term 5-passage, 4-day growth assay. Optimized component concentrations shown with a diagonal hash. **(A)** Schematic of passaging schedule. **(B)** Comparison of the effect of recombinant human insulin concentration on relative growth ( $n = 10$ ). **(C)** L-ascorbic acid 2-phosphate ( $n = 10$ ). **(D)** Recombinant transferrin ( $n = 10$ ). **(E)** Sodium selenite ( $n = 5$ ). **(F)** In-house made FGF2-G3 ( $n = 6$ ). **(G)** NODAL ( $n = 5$ ). **(H)** Activin A ( $n = 5$ ). **(I)** In-house made TGFβ3 after 9 passages compared to commercial TGFβ1 ( $n = 9$ ). **(J)** Addition of NRG1 to 40  $\text{ng ml}^{-1}$  FGF2-G3 ( $n > 5$ ). **(K)** Final B8 formula.  $n =$  full experimental replicates, unpaired Student's T-test,  $*P \leq 0.05$ ,  $**P \leq 0.01$ ,  $***P \leq 0.005$ ,  $****P \leq 0.0001$ , n.s. = not significant.



**Figure 4. Qualification of B8 as Suitable for hiPSC Generation and Culture.** (A) Demonstration of maintenance of pluripotency markers in 29 hiPSC lines derived in B8 assessed by flow cytometry. (B) Expression of pluripotent markers in a variety of B8-derived hiPSC lines. (C) Example G-banding karyotype analysis of four hiPSC lines derived in B8 from blood. (D) hiPSC growth at low seeding densities in B8 compared to E8 ( $n = 8$ ). (E) Assessment of stimulation of phospho-ERK after media had been stored at 37 °C for 2 or 7 days, comparing in-house generated FGF2-G3 to a commercial FGF2 (Peprotech). hiPSC were starved of FGF2 for 24 h then treated with the indicated media for 1 h before collection for Western blot. Total ERK was used as a loading control.



**Figure 5. Optimization of Weekend-Free Passaging Schedule that is Still Compatible with Monolayer Differentiation. (A)** Establishment of an optimal 4-day media change schedule. **(B)** 7 day passage with media change schedule. **(C)** 7 day passage only schedule. **(D)** Comparison of growth when using two 7-day weekend-free passaging schedules with or without addition of 0.5 mg ml<sup>-1</sup> albumin ( $n = 2$ ). **(E)** Comparison the addition of varying levels of albumin (mg ml<sup>-1</sup>) to a 7-day passage and media change schedule ( $n = 4$ ). **(F)** Cardiac differentiation efficiency when using 7-day passage and media change schedule ( $n = 5$ ). **(G)** Endothelial differentiation efficiency when using 7-day passage and media change schedule ( $n = 6$ ). **(H)** Endothelial differentiation efficiency when using 7-day passage and media change schedule ( $n = 5$ ).

**A****B**


|   | CDM-BSA <sup>1</sup> | DC-HAIF <sup>2</sup> | hESF9T <sup>3</sup> | FTDA <sup>4</sup> | iDEAL <sup>5</sup> | AKIT <sup>6</sup> | E8       | B8  |
|---|----------------------|----------------------|---------------------|-------------------|--------------------|-------------------|----------|-----|
| DMEM/F12 (l)  | 1                    | 1                    | ESF                 | 1                 | 1                  | 1                 | 1        | 1   |
| L-ascorbic acid 2-phosphate ( $\mu\text{g ml}^{-1}$ ) | 1.25                 | 50                   | 100                 | -                 | -                  | 64                | 64       | 200 |
| Insulin ( $\mu\text{g ml}^{-1}$ )                     | 5+7                  | -                    | 10                  | 5                 | -                  | 20                | 20       | 20  |
| IGF1 LR3 ( $\text{ng ml}^{-1}$ )                      | -                    | 200                  | -                   | -                 | 240                | -                 | -        | -   |
| Transferrin ( $\mu\text{g ml}^{-1}$ )                 | 3.75+15              | 10                   | 5                   | 5                 | 12                 | 10                | 10       | 20  |
| Sodium selenite ( $\text{ng ml}^{-1}$ )               | 2.5                  | 17.3                 | 3.5                 | 5                 | 15.4               | Yes               | 14       | 20  |
| FGF2 ( $\text{ng ml}^{-1}$ )                          | 12                   | 8                    | 10                  | 10                | 51                 | -                 | 100      | 40  |
| NRG1 ( $\text{ng ml}^{-1}$ )                          | -                    | 10                   | -                   | -                 | 21                 | -                 | -        | 0.1 |
| Activin A ( $\text{ng ml}^{-1}$ )                     | 10                   | 10 (1)               | -                   | 5                 | -                  | -                 | -        | -   |
| TGF $\beta$ ( $\text{ng ml}^{-1}$ )                   | -                    | -                    | 2                   | 0.2               | 2                  | -                 | 2        | 0.1 |
| NODAL ( $\text{ng ml}^{-1}$ )                         | -                    | -                    | -                   | -                 | -                  | -                 | (or 100) | -   |
| BMP inhibitor (nM)                                    | -                    | -                    | -                   | 50                | -                  | -                 | -        | -   |
| Bovine albumin ( $\text{mg ml}^{-1}$ )                | 0.2+5                | 20                   | -                   | -                 | -                  | -                 | -        | -   |
| Human albumin ( $\text{mg ml}^{-1}$ )                 | -                    | -                    | 0.0047              | 0.1               | 0.4                | -                 | -        | -   |
| 2-mercaptoethanol (mM)                                | -                    | 0.1                  | 0.01                | -                 | -                  | -                 | -        | -   |
| 1-thioglycerol ( $\mu\text{g ml}^{-1}$ )              | 450                  | -                    | -                   | -                 | -                  | -                 | -        | -   |
| Lipids (%)  | 1                    | -                    | -                   | 1                 | 0.1                | -                 | -        | -   |
| NEAA (%)  | -                    | 1                    | -                   | -                 | 1.95               | -                 | -        | -   |
| 1-azakenpauillone ( $\mu\text{M}$ )                   | -                    | -                    | -                   | -                 | -                  | 0.5               | -        | -   |
| ID-8 ( $\mu\text{M}$ )                                | -                    | -                    | -                   | -                 | -                  | 0.5               | -        | -   |
| Tacrolimus/FK506 (pM)                                 | -                    | -                    | -                   | -                 | -                  | 5-200             | -        | -   |

- Hannan et al., *Nat Protocols* 2013, basal media is 50:50 Advanced DMEM/F12:IMDM. Contributions from Advanced DMEM/F12 have been included.
- Wang et al., *Blood* 2007, and Robins and Schulz 2009, also contains transferrin and sodium selenite derived from Corning Trace Elements–A, –B, and –C. 1  $\text{ng ml}^{-1}$  activin A was sufficient for large-scale culture.
- Yamasaki et al., *PLoS One* 2014, also contains 10  $\mu\text{M}$  2-ethanolamine and 100  $\text{ng ml}^{-1}$  heparin sulfate sodium salt and uses ESF without HEPES (Furue et al., *In Vitro Cell Dev Biol Anim* 2005), human albumin is recombinant and conjugated with oleic acid.
- Frank et al., *PLoSOne* 2012, insulin, transferrin, and sodium selenite from ITS (Corning 354350), updated concentrations taken from Quaranta et al., *eLife* 2018, also use 2 nM Wnt-C59 for some lines.
- Marinho et al., *Sci Rep* 2015. Also contains 1  $\mu\text{M}$  pipercolic acid, 1 mM GABA
- Yasuda et al., *Nat Biomed Eng* 2018. use DMEM/F12 with trace elements (ammonium molybdate, ammonium metavanadate, stannous chloride, sodium selenite, magnesium sulfate, nickel chloride, and sodium metasilicate)

**C**

| Manufacturer                     | Catalog no. | HEPES (mM) | D-glucose ( $\text{g l}^{-1}$ ) | Sodium pyruvate (mM) | L-glutamine (mM) | pH      | mOsm $\text{l}^{-1}$ | $\text{NaHCO}_3$ ( $\text{mg l}^{-1}$ ) |
|----------------------------------|-------------|------------|---------------------------------|----------------------|------------------|---------|----------------------|---|
| Corning (1 l)                    | 10-092-CM   | 15         | 3.151                           | 1                    | 2.5              | 7.0-7.4 | 280-340              | 2438                                    |
| Gibco (500 ml)                   | 11330-032   | 15         | 3.151                           | 0.5                  | 2.5              | 7.0-7.4 | 290-320              | 1200                                    |
| HyClone (1 l)                    | SH30023.02  | 15         | 3.151                           | 0.5                  | 2.5              | 6.9-7.3 | 280-310              | 1200                                    |
| Lonza (500 ml)                   | 12-719F     | 25         | 3.151                           | 1                    | 2.5              | 7.0-7.4 | 260-290              | 1200                                    |
| Sigma (500 ml)                   | D8437       | 15         | 3.150                           | 0.5                  | 2.5              | 7.0-7.6 | 288-318              | 1200                                    |
| Sigma (powder, w/trace elements) | D0547       | 0          | 3.150                           | 0.5                  | 2.5              | 7.1-7.7 | 270-298              | 0                                       |

**Figure S1. Optimization of Matrix Concentration and Comparison of Media Formulae.** **a**, Relative growth of hiPSC on dilutions of Matrigel (Corning) or Cultrex (Trevigen), Cultrex is equivalent to Geltrex (Gibco). **b**, Comparative table of existing published media formulae for hPSC growth. **c**, Comparison of commercially available DMEM/F12 formulae that contain D-glucose, L-glutamine, phenol red, and HEPES. D0547 is the formula used by Yasuda *et al.*, 2018.

**B****FGF1**

MFNLPPGNYK KPKLLYCSNG GHFLRILPDG TVDGTRDRSD QHIQLQLSAE SVGEVYIKST ETGQYLAMDT  
 DGLLYGSQTP NEECLFLERL EENHYNTYIS KKHAEKNWFV GLKKNNGSCKR GPRTHYGQKA ILFLPLPVSS  
 D

**FGF1-4X**

MFNLPPGNYK KPKLLYCSNG GHFLRILPDG TVDGTRDRSD **PHIQLQLIAE** SVGEVYIKST ETGQYLAMDT  
 DGLLYGSQTP NEECLFLERL **EENGYNTYIS** KKHAEKNWFV **GLNKNNGSCKR** GPRTHYGQKA ILFLPLPVSS  
 D

**FGF2**

MAAGSITTLP ALPEDGGSGA FPPGHFKDPK RLYCKNGGFF LRIHPDGRVD GVREKSDPHI KLQLQAEERG  
 VVSIKGVCAN RYLAMKEDGR LLASKCVTDE CFFFERLESN NYNTYRSRKY TSWYVALKRT GQYKLGSKTG  
 PGQKAILFLP MSAKS


**FGF2 K128N**

MAAGSITTLP ALPEDGGSGA FPPGHFKDPK RLYCKNGGFF LRIHPDGRVD GVREKSDPHI KLQLQAEERG  
 VVSIKGVCAN RYLAMKEDGR LLASKCVTDE CFFFERLESN NYNTYRSRKY TSWYVAL**N**RRT GQYKLGSKTG  
 PGQKAILFLP MSAKS

**FGF2-G3 R31L, V52T, E54D, H59F, L92Y, S94I, C96N, S109E, T121P**

MAAGSITTLP ALPEDGGSGA FPPGHFKDPK **L**LYCKNGGFF LRIHPDGRVD **GTRDKSDPFI** KLQLQAEERG  
 VVSIKGVCAN RYLAMKEDGR **LYAIKNTVDE** CFFFERLE**N** NYNTYRSRKY **PSWYVALKRT** GQYKLGSKTG  
 PGQKAILFLP MSAKS


**Figure S2. Plasmids used to Generate Recombinant Growth Factors. (A)** FGF2-K128N demonstrating dual 6xHis site for purification and thrombin cleavage site. **(B)** Amino acid sequences used to generate modified FGF2 plasmids.



**Figure S3. Optimization of additional human pluripotent stem cell medium constituents.** (A) Relative growth with commercial TGF $\beta$ 1 after 9 passages ( $n = 9$ ). (B) Relative growth in medium with TGF $\beta$ 1 and Activin A, after 5 passages ( $n = 5$ ). (C) Commercial TGF $\beta$ 3 short term ( $n = 3$ ). (D) Commercial TGF $\beta$ 3 after 9 passages compared to commercial TGF $\beta$ 1 ( $n = 9$ ) (compare to **Figure 3I**, TGF $\beta$ 3 (in-house)). (E) Addition of commercial NRG1 to FGF2-G3-containing media ( $n > 5$ ). (F) Relative growth in medium with NRG1 but without FGF2, long-term assay ( $n = 5$ ). (G) in-house NRG1 with thrombin fusion protein cleaved by two different methods, short-term assay ( $n = 8$ ) (compare to **Figure 2J**, commercial NRG1).







**B**

| B8 formula for 100 l optimized for fastest growth |                                   |
|---|-----------------------------------|
| 100 l DMEM/F12                                    | Corning 10-092-CM                 |
| 20 g L-ascorbic acid 2-phosphate                  | Fujifilm Wako 321-44823           |
| 2 g insulin                                       | Gibco A11382ij                    |
| 2 g transferrin                                   | InVitria Optiferrin 777TRF029-10G |
| 2 mg sodium selenite                              | MilliporeSigma S5261-10G          |
| 4 mg FGF2-G3                                      | Made in-house                     |
| 10 µg NRG1  | Made in-house                     |
| 10 µg TGFβ3                                       | Made in-house                     |

**C**

| B8 formula for 100 l optimized for lowest cost |                                   |
|--|-----------------------------------|
| 100 l DMEM/F12                                 | Corning 10-092-CM                 |
| 20 g L-ascorbic acid 2-phosphate               | Fujifilm Wako 321-44823           |
| 0.5 g insulin                                  | Gibco A11382ij                    |
| 0.5 g transferrin                              | InVitria Optiferrin 777TRF029-10G |
| 2 mg sodium selenite                           | MilliporeSigma S5261-10G          |
| 4 mg FGF2-G3                                   | Made in-house                     |
| 10 µg NRG1                                     | Made in-house                     |
| 10 µg TGFβ3                                    | Made in-house                     |

**D**

**Generating B8 supplements (for 100 l)**  
 Shown below are directions for making 100 × B8 supplement aliquots suitable for generated 100 liters of B8. B8 contains high levels of ascorbic acid and therefore must be made as a two-aliquot system.

**Aliquot 1:** 400 mg ml<sup>-1</sup> L-ascorbic acid 2-phosphate: Add 50 ml of room temperature cell culture water (Corning) to a 50 ml Falcon tube, then slowly add 20 g of L-ascorbic acid 2-phosphate. Mix by inversion until clear, filter sterilize (PES 0.2 µm filters) and make 100 x 500 µl aliquots in sterile 1.5 ml microfuge tubes and store at -20 °C.

**Aliquot 2:** Place 46 ml of room temperature cell culture water in a 50 ml Falcon tube, add 2 g (or 0.5 g) of insulin, add 1400 µl (or 350 µl) of 1 N HCl to dissolve (~pH 3), mix until clear and then add 200 µl (or 50 µl) 10 N NaOH (~pH 7.4), then add 2 g (or 0.5 g) of transferrin, 1 mL of 2 mg ml<sup>-1</sup> sodium selenite, 400 µl of 10 mg ml<sup>-1</sup> FGF2-G3, 100 µl of 100 µg ml<sup>-1</sup> TGFβ3, and 100 µl of 100 µg ml<sup>-1</sup> NRG1. Mix by inversion until clear, filter sterilize (PES 0.2 µm filters) and make 500 µl aliquots in sterile 1.5 ml microfuge tubes and store at -20 °C.

To make a 1 l bottle of B8 thaw one aliquot at RT and aseptically add to 1 l of DMEM/F12 along with 72 ml of cell culture water (to bring osmolarity to 310 mOsm).

**Figure S5. Generation of B8. (A)** Cost comparison between B8 and commercial media. **(B)** B8 formula optimized for fasted growth. **(C)** B8 formula optimized for lowest cost. **(D)** Short protocol for the generation of B8 supplement aliquots.